Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rajesh Patel

Addiction Psychiatry Bronx, NY Medical Doctor

NPI 1003908005 CMS profile 181837

1276 Fulton Ave, Bronx, NY 10456

Open in the dashboard

General payments

$516

21 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rajesh Patel of Bronx, NY is reported in the CMS Open Payments database as having received $516 across 21 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Addiction Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $161 8
2024 General $130 1
2023 General $44 2
2022 General $22 1
2021 General $65 2
2020 General $12 1
2019 General $81 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rajesh Patel
  • Addiction Psychiatry median
  • Middle half of Addiction Psychiatry
  • National median

In program year 2025, general payments to Rajesh Patel were reported at $161. Among 180 Addiction Psychiatry profiles paid that year, the median was $138 and the middle half received between $45 and $421.

Show as a table
Year Rajesh Patel Addiction Psychiatry median Middle half National median
2019 $81 $142 $56–$476 $163
2020 $12 $78 $21–$210 $114
2021 $65 $112 $35–$458 $132
2022 $22 $113 $39–$343 $149
2023 $44 $134 $47–$429 $160
2024 $130 $129 $42–$349 $164
2025 $161 $138 $45–$421 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Spinal Simplicity, LLC $130 1 payment
  2. E.R. Squibb & Sons, L.L.C. $57 2 payments
  3. AbbVie, Inc. $52 2 payments
  4. ITI, Inc. $47 1 payment
  5. Otsuka America Pharmaceutical, Inc. $35 2 payments
  6. Axsome Therapeutics, Inc. $29 2 payments
  7. Validus Pharmaceuticals LLC $23 2 payments
  8. Janssen Pharmaceuticals, Inc $20 1 payment
  9. Cardiva Medical, Inc. $18 1 payment
  10. Vanda Pharmaceuticals Inc. $18 1 payment
  11. Other $87 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $469 20 payments
  2. Education $47 1 payment
Products named General payments · program years 2019–2025
  1. HA MINUTEMAN G3-R $130 1 payment
  2. COBENFY $57 2 payments
  3. VRAYLAR $52 2 payments
  4. CAPLYTA $47 1 payment
  5. REXULTI $35 2 payments
  6. Auvelity $29 2 payments
  7. Equetro $23 2 payments
  8. SPRAVATO $20 1 payment
  9. Cardiva VASCADE 6/7F VCS $18 1 payment
  10. FANAPT $18 1 payment
  11. Other $114 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

2,652

Median for Psychiatry: 574

Drug cost

$99,964

Median for Psychiatry: $27,624

Branded share of claims

18%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lurasidone Hcl Generic 31 $23,924
Chlorpromazine Hcl Generic 13 $20,311
Trintellix Vortioxetine Hydrobromide Brand 20 $9,294
Paliperidone Er Paliperidone Brand 13 $6,574
Bupropion Xl Bupropion Hcl Brand 128 $3,058
Divalproex Sodium Er Divalproex Sodium Brand 56 $2,647
Quetiapine Fumarate Generic 151 $2,609
Divalproex Sodium Generic 85 $2,474
Aripiprazole Generic 65 $2,362
Risperidone Generic 154 $2,092

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$55,937

Medicare's payments for the services billed

Medicare patients

167

Average age 59

Services billed

745

93 women, 74 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Depression 63%
Diabetes 38%
Arthritis 34%
Ischemic heart disease 19%
Chronic kidney disease 18%
Osteoporosis 14%
Heart failure 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

21 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Addiction Psychiatry in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record